Maravai LifeSciences Partners with Avantor to Boost Nucleic Acid Product Distribution in EMEA

Maravai LifeSciences Enhances Distribution of Nucleic Acid Products in EMEA

Maravai LifeSciences Holdings, through its subsidiary TriLink BioTechnologies, has formed a strategic partnership with Avantor, Inc. to improve the distribution of its nucleic acid products across Europe, the Middle East, and Africa (EMEA). This collaboration aims to streamline the ordering process, thereby reducing lead times for customers in these regions and increasing access to TriLink’s innovative nucleic acid technologies. TriLink, with over 25 years of expertise in the development of nucleic acid products, is particularly recognized for its advancements in mRNA-based therapeutics, a field that has gained significant prominence in recent years.

The partnership with Avantor will enable TriLink to broaden the availability of essential products such as CleanCap® cap analogs, catalog mRNAs, and a variety of modified and unmodified nucleotides. Additionally, high-performance IVT enzymes, including CleanScribe® RNA Polymerase, will now be more accessible to clients in EMEA. In the coming months, customers will be able to order these products via VWR’s eCommerce platform, MarketSource, thus further enhancing the convenience of procurement. Becky Buzzeo, Chief Commercial Officer at TriLink, underscores the importance of this partnership in addressing the increasing demand for innovative nucleic acid solutions, which are crucial for life-changing therapeutic research.

TriLink BioTechnologies is dedicated to the advancement of nucleic acid therapeutics, vaccines, and diagnostics, offering high-quality technology and Contract Development and Manufacturing Organization (CDMO) services. The company's expanding portfolio includes award-winning products like CleanCap® M6 and various mRNA raw materials, coupled with advanced scale-up capabilities. With its established expertise, TriLink plays a vital role in assisting pharmaceutical companies, biotech innovators, and governments in overcoming major healthcare challenges, including the rapid delivery of COVID-19 vaccines and the development of treatments for a range of conditions such as oncology, infectious diseases, cardiology, and neurological disorders.

In summary, the partnership between TriLink and Avantor represents a significant step towards enhancing the availability of critical nucleic acid products in the EMEA region. This collaboration not only addresses the growing demand for advanced therapeutic solutions but also positions TriLink as a key player in the global market for nucleic acid technologies. The accessibility of these resources will play an important role in supporting ongoing research and development efforts aimed at tackling pressing health challenges.